ETFMG Treatments, Testing and Advancements ETF (GERM) Research
This fund aims to replicate the investment performance of U.S.-listed companies, including equity shares and depositary receipts, that are primarily engaged in two sectors: either researching, developing, and bringing to market treatments or vaccines for infectious diseases, or producing, researching, and supplying biological diagnostic tests for patients. At least 80% of the fund's total assets will be invested in the specific securities that constitute its underlying index. It is important to note that this fund is structured as non-diversified.
Market snapshot
- Symbol
- GERM
- Price
- $19.16
- Day change
- -0.29%
- Market cap
- $9.6M
- 52-week range
- 16.32-20.1994
- Sector
- Financial Services
- Industry
- Asset Management
Peer companies
- B.A.D. ETF (BAD)
- Global X MSCI China Information Technology ETF (CHIK)
- Asian Growth Cubs ETF (CUBS)
- AAM S&P Emerging Markets High Dividend Value ETF (EEMD)
- ERShares NextGen Entrepreneurs ETF (ERSX)
- Hartford Schroders Commodity Strategy ETF (HCOM)
- Hartford Schroders ESG US Equity ETF (HEET)
- Nifty India Financials ETF (INDF)
Open ETFMG Treatments, Testing and Advancements ETF (GERM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.